Inovio opens phase 2 trial for VGX-3100 in third indication to treat HPV
Inovio announced it has commenced a Phase 2 clinical trial to evaluate efficacy of VGX-3100 in adult men and women with HPV-related anal dysplasia. Anal HSIL or dysplasia is the precursor to anal cancer, which is estimated to cause more than 1,100 deaths in the U.S. in 2018. May 21, 2018